ArticleOncotarget2014

Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.

Rafaela Andrade-Vieira et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.